Related Experiment Video
Updated: Aug 1, 2026
08:55
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia
Swarnali Acharyya1, Matthew E R Butchbach, Zarife Sahenk
1Human Cancer Genetics Program, The Ohio State University, Columbus, Ohio 43210, USA.
Cancer Cell
|November 16, 2005
Summary
Cancer-induced muscle wasting, or cachexia, involves early changes to the dystrophin glycoprotein complex (DGC). DGC dysfunction is a key factor in skeletal muscle loss during cancer, mirroring its role in muscular dystrophy.
Area of Science:
- Muscle physiology
- Cancer biology
- Molecular mechanisms of disease
Background:
- Cachexia causes approximately one-third of cancer-related deaths.
- The precise mechanisms driving skeletal muscle wasting in cachexia are not fully understood.
- The dystrophin glycoprotein complex (DGC) is crucial for muscle membrane integrity.
Purpose of the Study:
- To investigate the role of the dystrophin glycoprotein complex (DGC) in cancer-induced skeletal muscle wasting (cachexia).
- To determine if DGC alterations are an early event in cachexia development.
- To explore the correlation between DGC deregulation and cachexia in human cancer patients.
Main Methods:
- Analysis of muscle membrane abnormalities in tumor-bearing mice.
- Quantification of dystrophin levels and DGC protein glycosylation.
- Comparison of muscle wasting in genetically modified mice (mdx and transgenic) with and without tumors.
- Correlation analysis of DGC alterations with cachexia severity in gastrointestinal cancer patients.
Main Results:
- Tumor-bearing mice showed muscle membrane abnormalities, reduced dystrophin, and altered DGC protein glycosylation.
- Muscle wasting was more severe in tumor-bearing mice lacking a functional DGC (mdx mice).
- Muscle wasting was reduced in mice engineered to block E3 ubiquitin ligase induction, suggesting a protective role.
- DGC deregulation was positively correlated with cachexia in patients with gastrointestinal cancers.
Conclusions:
- Alterations in the dystrophin glycoprotein complex (DGC) are a critical early event in cancer-induced cachexia.
- DGC dysfunction plays a significant role in skeletal muscle wasting during cancer, similar to its role in muscular dystrophy.
- Targeting DGC pathways may offer a therapeutic strategy for mitigating muscle loss in cancer patients.
Related Concept Videos
01:26Cross-bridge Cycle
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
00:50Anaphase Promoting Complex
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...